We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-7.96%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$942M
Cap. Flow
-$780M
Cap. Flow %
-76.64%
Top 10 Hldgs %
36.57%
Holding
87
New
6
Increased
6
Reduced
47
Closed
24

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$15.3M
2
JANX icon
Janux Therapeutics
JANX
+$9.52M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.05M
4
DXCM icon
DexCom
DXCM
+$5.77M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.58M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$48.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$43.4M
3
BSX icon
Boston Scientific
BSX
+$39.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$29.6M
5
ILMN icon
Illumina
ILMN
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 98.53%
2 Miscellaneous 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.92B
$62.6M 6.15%
2,873,000
-44,231
-2% -$1.14M
BSX icon
2
Boston Scientific
BSX
$67.9B
$46M 4.52%
515,000
-447,000
-46% -$39.3M
JANX icon
3
Janux Therapeutics
JANX
$1.1B
$39.7M 3.9%
741,900
+179,900
+32% +$9.52M
NTRA icon
4
Natera
NTRA
$47B
$35.4M 3.48%
223,800
-332,600
-60% -$48.4M
EXAS
5
DELISTED
Exact Sciences
EXAS
$33.9M 3.33%
603,011
+15,011
+3% +$934K
ISRG icon
6
Intuitive Surgical
ISRG
$132B
$33.8M 3.32%
64,800
-83,400
-56% -$43.4M
CGON icon
7
CG Oncology
CGON
$6.59B
$31.5M 3.09%
1,097,800
-558,200
-34% -$19.1M
UNH icon
8
UnitedHealth
UNH
$353B
$30.4M 2.98%
60,000
-27,400
-31% -$15.6M
NBIX icon
9
Neurocrine Biosciences
NBIX
$15.7B
$30.1M 2.95%
220,400
-239,600
-52% -$29.6M
IDYA icon
10
IDEAYA Biosciences
IDYA
$3.87B
$29M 2.84%
1,126,700
-246,300
-18% -$6.97M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$28.9M 2.84%
234,500
-196,500
-46% -$23.2M
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$5.94B
$27.5M 2.71%
666,200
-64,904
-9% -$2.7M
ACHC icon
13
Acadia Healthcare
ACHC
$2.66B
$26.1M 2.56%
658,000
-327,000
-33% -$14.7M
ARVN icon
14
Arvinas
ARVN
$600M
$26M 2.56%
1,358,000
-139,000
-9% -$3.38M
GKOS icon
15
Glaukos
GKOS
$10.6B
$25.5M 2.5%
170,000
-174,900
-51% -$24.1M
DXCM icon
16
DexCom
DXCM
$34.3B
$24.7M 2.43%
318,000
+78,000
+33% +$5.77M
TMO icon
17
Thermo Fisher Scientific
TMO
$230B
$23.2M 2.28%
44,600
-24,000
-35% -$13.2M
HUM icon
18
Humana
HUM
$46.3B
$22.6M 2.22%
89,200
-40,500
-31% -$10.9M
KYMR icon
19
Kymera Therapeutics
KYMR
$9.82B
$20.1M 1.98%
500,000
– –
AVTR icon
20
Avantor
AVTR
$9.86B
$20M 1.96%
947,000
-288,000
-23% -$6.48M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.74B
$19.8M 1.95%
1,500,000
-955,000
-39% -$16.3M
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$19.5M 1.92%
1,165,800
-966,200
-45% -$16M
RVMD icon
23
Revolution Medicines
RVMD
$44.6B
$19.5M 1.92%
446,200
-343,800
-44% -$17.4M
XENE icon
24
Xenon Pharmaceuticals
XENE
$5.81B
$18.6M 1.82%
474,000
-344,000
-42% -$14.2M
THC icon
25
Tenet Healthcare
THC
$21.5B
$17.3M 1.7%
137,000
-116,000
-46% -$17.2M
1
2 3 4

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q4 2024 Portfolio in Review

As of Q4 2024, Avidity Partners Management held 87 positions worth $1.02B, down 48% from $1.96B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Avidity Partners Management withdrew a net $780M in Q4 2024, closing 24 positions and reducing 47 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $5.98M.

  • Avidity Partners Management's largest Q4 2024 buy was Regeneron Pharmaceuticals: 8,400 shares worth $5.98M.
  • Avidity Partners Management added most to Transmedics in Q4 2024, an estimated $15.3M increase.
  • Avidity Partners Management's biggest Q4 2024 reduction was Natera, cutting an estimated $48.4M.
  • Avidity Partners Management fully exited BioMarin Pharmaceuticals in Q4 2024, selling an estimated $22.5M.
  • Avidity Partners Management's ten largest holdings make up 37% of its $1.02B portfolio in Q4 2024.
  • Avidity Partners Management opened 6 new positions and closed 24 in Q4 2024.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $1.02B.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.